WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Dr. Jimmy Li, CEO of WuXi XDC, to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Shanghai, China January 4, 2024 WuXi XDC Cayman Inc.(“WuXi XDC”, or the “Company”, stock code: 2268.HK ), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (“ADC”) and broader...WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan 3, 2024—WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform...WuXi XDC Received Four Prestigious Awards for Solid Performance and Capability
WuXi XDC(stock code: 2268.HK), a leading global Contract, Research, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has received four awards from industry’s leading and premier institutions and...
WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange
Hong Kong, China, November 17, 2023 – WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (“ADC”) and the broader...
WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards
WuXi XDC, a leading global Contract, Research, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the “Best Contract Development Manufacturing Organization (CDMO)” prize at...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?